Drug Trial Radar · NCT07897240
A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Triastek, lnc.Industry
- Sponsor type
- Industry
- Collaborators
- Second Affiliated Hospital of Soochow University
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the effect of food (a high-fat, high-calorie meal) on the PK of a single oral dose of budesonide delayed release tablet in healthy participants. The main questions it aims to answer are : (1) Does a high-fat, high-calorie meal significantly alter the plasma exposure (Cmax, AUC) of budesonide following oral administration of D23A? ( 2) How does food intake affect the absorption rate (Tmax, Tlag) and other PK parameters of D23A? Researchers will compare the plasma PK parameters of D23A administered under fasted conditions versus fed conditions to see if a high-fat, high-calorie meal has a significant impact on the bioavailability and absorption kinetics of D23A . Participants will receive a single oral dose of 16 mg D23A (4 tablets) in each period of the crossover study, with one period under fasted conditions and the other under fed conditions (after consuming a high-fat, high-calorie meal) . The study will also monitor and record any adverse events (AEs) to evaluate the safety and tolerability of D23A under fed conditions .
Conditions
- IgA Nephropathy
Interventions
Budesonide delayed release tabletDrug
3D printing tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: up to 48 hours post-dose
- AUC0-tTime frame: up to 48 hours post-dose
- AUC0-∞Time frame: up to 48 hours post-dose
- TmaxTime frame: up to 48 hours post-dose
- TlagTime frame: up to 48 hours post-dose
- AUC0-4Time frame: up to 48 hours post-dose
- AUC4-tTime frame: up to 48 hours post-dose
- t1/2Time frame: up to 48 hours post-dose
- λzTime frame: up to 48 hours post-dose
- AUC_%ExtrapTime frame: up to 48 hours post-dose
- CL/FTime frame: up to 48 hours post-dose
- VZ/FTime frame: up to 48 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.